Reports Q2 revenue $240.678M, consensus $238.39M. “In the second quarter, we increased U.S. pump shipments while strengthening our business model and improving operational efficiency,” said John Sheridan, president and chief executive officer. “Looking at the remainder of the year, we are advancing our product development and commercial initiatives, which positions us well for sustained double-digit growth and enhanced profitability.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Notable companies reporting after market close
- Tandem Diabetes price target lowered to $38 from $48 at Leerink
- Tandem Diabetes downgraded to Sell from Neutral at Citi
- Wells says CBP proposal for CGMs expected, insulin pumps inclusion ‘a surprise’
- Diabetes device maker shares slide after payment scheduling proposal